(MENAFN - Arab News) American cardiologist and researcher Dr. Yerem Yeghiazarians is currently on a visit to the Kingdom to gauge interest in the establishment of a stem-cell research facility here.
Leading Saudi businessmen Hamad and Khalid Al-Zamil are interested in advancing the research initiative and invited Yeghiazarians to meet business leaders, arranged lectures and toured him around various hospitals to garner support for his pioneering project.
Dr. Yeghiazarians believes stem cell treatment may be the only hope for thousands of people worldwide who suffer from heart problems. Dr. Yeghiazarians speaks to Arab News journalist Siraj Wahab on the latest developments in the field.
Dr. Yeghiazarians, welcome to Saudi Arabia. Is this your first visit? Please tell us more about yourself and your medical background. Yes, this is my first time in Saudi Arabia. It is truly an honor being in the Kingdom. I am a cardiologist. I also do interventional cardiology, meaning I do procedures in patients who have blockages in their arteries or who have heart attacks. I did my training mostly in the United States. My medical school training was at Johns Hopkins Medical School in Maryland. After that I spent eight years at Harvard Medical School at the Brigham and Women's Hospital, one of their main teaching hospitals. It is one of the most respected training institutions in the country, if not the best. I finished my internal medicine training there and decided to do cardiology training. When I completed my clinical training in cardiology, I was asked to go back and take a chief residency for the whole Brigham and Women's Hospital internal medicine residency program. I was the chief resident in charge of training 170 trainees in internal medicine that year. I finished my training for interventional cardiology and did my research at Harvard and in 2003 was recruited to the University of California, which is a world-renowned medical and research institution. I was doing interventional cardiology and started a cardiac stem cell program.
What was the level of interest in 2003 to stem cell research and what exactly is it? Back in 2003, it was a very new research endeavor. The basic idea of our research is to use stem cells to improve heart function after a heart attack. What tends to happen to patients who suffer from a heart attack is because of the lack of blood flow and the blockage that develops in the heart artery, the heart muscle becomes damaged and scarred. The heart, unlike the other organs in the body, doesn't have enough capacity to regenerate itself. Once you have a heart attack that muscle is damaged. It is replaced by scar tissue. Over time the heart loses its pumping capacity and is unable to pump blood out of the heart to rest of the body. It is like pouring water into a balloon. The balloon gets bigger and loses its pumping capacity. Blood or fluid builds up in the lungs and leads to congestive heart failure or cardiomyopathy. It is the number one killer in the developed world and results from risk factors such as diabetes, smoking or high blood pressure.
How do you treat congestive heart failure? Over the last 20 to 30 years, a lot of effort has been made to develop medications to improve heart function after a heart attack. None of the therapy we have is adequate to help all our patients. Some make progress but they need mechanical devices like heart pumps. Sometimes even that fails. The only way is to do a heart transplant. But even in the United States we do less than 3,000 heart transplants a year. Thousands of patients need advanced therapy. Unfortunately, none of the drugs today can replace heart scar tissue with a beating, functional muscle cell. The only hope we have is to use stem cells to regenerate the scar tissue and replace it with a heart muscle cell and improve heart function. This will eliminate the need for mechanical intervention or a heart transplant. Heart transplants are very rare and in many parts of the world it is impossible for patients to have them.
How far are we into stem cell research? There are different types of stem cells we can use for treating ailments. There are adult stem cells and there are embryonic stem cells. There is a new development called induced pluripotent stem cells, otherwise known as IPS cells. This was an amazing discovery. Last month the Nobel Prize in Medicine went to the two people who discovered it. The scientists took a skin cell and genetically manipulated it and make this cell into a stem cell or a younger cell. We all come from a young cell. This discovery meant we can turn the clock back to an immature cell from which different types of cells can be created, enabling us to treat all conditions in the future. It is still early days but there is a lot of promise. We have come a long way using adult stem cells in ongoing clinical trials, which appear to show a lot of promise. In the future the hope is to use these cells to replace the scar tissue with a viable heart muscle cell.
Do you intend to establish a research facility in Saudi Arabia? From my understanding there is not much research going on in this field here or in the region. So it is an honor for me to come here and introduce the research we are doing at the University of California and to extend our knowledge to the folks here in the Middle East and Saudi Arabia specifically. The idea is to garner interest and to see if people are interested in collaborating with us in starting a similar project here. We are very hopeful that in the future we can collaborate to advance the research we have for the treatment of heart patients.
What kind of laboratory do you have in California? We do basic research that involves growing cells at my laboratory. We also have small-animal models and large-animal models whereby we can study them before we introduce them to patients. It would be fantastic if we could set up a similar research program here. I am trying to monitor the interest among people here. I need to know what facilities are currently available and find out how we can introduce larger facilities to the region advance the research collaboratively.
What is the cost to set up a similar one here? It is hard to put a figure on it. It depends on how big a program people here would be interested in. We are talking about millions of dollars. I will give you an example. At the University of California about two or three years ago, we created a whole new building specifically to study stem cells and that cost about 200 million. We have more than 20 investigators who study stem cells for different disease conditions, not just the heart but for other conditions too. Stem cells could some day potentially be used for patients following a stroke and for patients with diabetes, kidney disease and liver failure. There are endless possibilities." This is the time to invest in it, to put a program together, because it is not that we are going to discover it over the next year or two. This is going to help our future generation, our medical students, create novel treatment for all kinds of diseases.
Original post:
Stem cell research facility considered for Saudi Arabia
- Stem Cell Therapy: Alternative Treatment to Hip & Knee ... - November 22nd, 2021
- How The Overlap Between Artificial Intelligence And Stem Cell Research Is Producing Exciting Results - Forbes - November 22nd, 2021
- Selma Blair Posts Nude Diving Photo After MS Stem Cell ... - November 22nd, 2021
- Stem Cell Therapy Reduces Need for Nearly 10% of Hip Replacements - Yale School of Medicine - November 22nd, 2021
- Stem cell therapy for heart failure lowers risk of adverse outcomes - Cardiovascular Business - November 22nd, 2021
- A second HIV patient may have been 'cured' of infection without stem cell treatment, in extremely rare case - CNN - November 22nd, 2021
- The Promise of Stem Cells to Help Children with Autism - Entrepreneur - November 22nd, 2021
- Global Cell Therapy Manufacturing Market Competition Forecast & Opportunities to 2026 - ResearchAndMarkets.com - Galveston County Daily News - November 22nd, 2021
- Dr Pengyi Yang wins National Stem Cell Foundation Metcalf Prize - News - The University of Sydney - November 22nd, 2021
- BioRestorative Therapies Enters into Letter of Intent with PRC Clinical - BioSpace - November 22nd, 2021
- SC21- 21st century cellular medicines specialists - The Thaiger - November 22nd, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- New hope for bowel cancer patients as fresh partnership between Carina Biotech and CellVec enables advancement of clinical trials. - Bio-IT World - November 22nd, 2021
- FDA Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery - Business... - November 22nd, 2021
- Mum with brain fog and pins and needles in hands devastated by 'ticking time bomb' MS - Mirror.co.uk - November 22nd, 2021
- CAR T-cell therapy: Hear from a Canadian patient - CTV News - November 8th, 2021
- Talaris therapy ends need for immune drugs in transplant patients - - pharmaphorum - November 8th, 2021
- Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL - OncLive - November 8th, 2021
- Parkinson's gene therapy restores responses to dopamine-boosting drug in mouse models - FierceBiotech - November 8th, 2021
- Studies: CAR-T therapies superior to standard treatment in blood cancer - STAT - November 8th, 2021
- Salit Discusses the Use of Staging and Grading for Patients With GVHD to Choose Appropriate Treatment - Targeted Oncology - November 8th, 2021
- Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates - BioSpace - November 8th, 2021
- Global Stem Cell Therapy Market Size, Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2026 - Northwest Diamond Notes - November 8th, 2021
- BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting &... - November 8th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results - Yahoo Finance - November 8th, 2021
- Bacterial Infections Linked with Unapproved Stem Cell Treatments - Contagionlive.com - October 28th, 2021
- Team finds way to enhance stem cell therapy for CNS injuries - BioPharma-Reporter.com - October 28th, 2021
- Stem cell therapy can help combat common symptoms of aging - The Mountaineer - October 28th, 2021
- Stem Cells Used to Treat Avascular Necrosis of the Femoral Head - Yale School of Medicine - October 28th, 2021
- Vitti Labs Announces FDA Approval of IND Application for Phase II Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Novel... - October 28th, 2021
- Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM (Antibody Recruiting Molecule) Platform, in Combination with NK Cell... - October 28th, 2021
- The Power of the Immune System: New Treatment for Painful Blood Cancer Side Effect - Curetoday.com - October 28th, 2021
- Global Cell Therapy Market Research Report 2021: Opportunities with the Approval of Kymriah and Yescarta Across Various Countries -... - October 28th, 2021
- Pursuing Optimal Therapy Remains a Challenge in Indolent B-Cell Lymphoma - Targeted Oncology - October 28th, 2021
- Stem Cell Therapy Market Research Report by Cell Source, by Type, by Therapeutic Application, by End-User, by Region - Global Forecast to 2026 -... - October 16th, 2021
- Harvard's R&D; alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 16th, 2021
- A New Line of Defense in Blood Cancer: Natural Killer Cell Therapy - Curetoday.com - October 16th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 16th, 2021
- Rheumatoid Arthritis Stem Cell Therapy Market By Type (Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant, Adipose Tissue Stem Cells) and By... - October 16th, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress - Yahoo Finance - October 16th, 2021
- Taking aim at the brain, Takeda strikes up cell therapy R&D; alliance with Immusoft - MedCity News - October 16th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 16th, 2021
- Newer Agents for DLBCL Show Potential for Earlier Use in the Course of Treatment - Targeted Oncology - October 16th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 16th, 2021
- Worldwide Cell Therapy Consumables Industry to 2031 - Featuring Bio-Techne, Irvine Scientific and Sartorius Among Others - PRNewswire - October 16th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 16th, 2021
- BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization -... - October 16th, 2021
- FTC Follows Through On Prioritizing Investigations Into False Advertising In Healthcare Markets - Media, Telecoms, IT, Entertainment - United States -... - October 16th, 2021
- Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Type That Could Explain Why Its So Aggressive - On Cancer - Memorial Sloan Kettering - October 16th, 2021
- Actress Jennifer Garner Visits with 7-Year-Old Girl Fighting B-cell Acute Lymphoblastic Leukemia; What is the Treatment for This Disease? -... - October 16th, 2021
- Four-year-old girl with stage four cancer trying to get to America for clinical trial - Lancashire Telegraph - October 16th, 2021
- Stem cell & gene therapy to treat osteogenesis imperfecta: hype or hope - Open Access Government - October 5th, 2021
- Chennai-based institute to begin clinical trial on stem cell therapy for liver disease - The New Indian Express - October 5th, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 5th, 2021
- Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission - Digital Journal - October 5th, 2021
- Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment - Yahoo Finance - October 5th, 2021
- Ready to Treat Over 80 Life-Threatening Diseases, Discover the Potential of Cord Blood during World Cord Blood Day 2021 - PRNewswire - October 5th, 2021
- Transforming Growth Factor Sales Gaining Traction & to reach US$ 709.9 Mn with Significant Development in Cell Therapy Research - PRNewswire - October 5th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WITN - October 5th, 2021
- Brazil investigates the use of stem cells in the treatment of covid-19 The Clare People - The Clare People - October 5th, 2021
- Indianapolis mother gives 13-year-old son with sickle cell disease a 2nd chance at life - WTHR - October 5th, 2021
- US FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | DNA RNA and... - October 5th, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 5th, 2021
- 'Survivor' winner Ethan Zohn opens up about his cancer battle: I was a healthy, young guy. You never expect it to be you. - Yahoo Life - October 5th, 2021
- The Best Skincare Treatments For Time-Crunched Moms (Or Anyone Else Who Only Has Five Minutes To Spare) - Forbes - October 5th, 2021
- [PDF] Stem Cell Therapy Market Size Strong Revenue and Generated Opportunities UNLV The Rebel Yell - UNLV The Rebel Yell - August 31st, 2021
- Mike Tysons weird stem cell treatment has helped transform incredible body at 55 - Daily Star - August 31st, 2021
- Acute Monocytic Leukemia: Causes, Symptoms, and Treatment - Healthline - August 31st, 2021
- UC Davis and the School of Medicine set new records in research funding - UC Davis Health - August 31st, 2021
- NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network - August 31st, 2021
- DHEC Supports Awareness and Education during National Sickle Cell Awareness Month - SCDHEC - August 31st, 2021
- The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation - DocWire News - August 31st, 2021
- Global Cryopreservation Equipment Market Report 2021-2028 - Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking... - August 31st, 2021
- Operational Highlights and Financial Results for the Year Ended June 30, 2021 - GlobeNewswire - August 31st, 2021
- Event to benefit 2 families with kids fighting cancer - Youngstown Vindicator - August 31st, 2021
- Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market - GlobeNewswire - August 31st, 2021
- Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults... - August 31st, 2021
- Thomas Smeenk with an update on the FDA Phase II clinical trial program of the Hemostemix blood-derived, stem cell therapeutics product (ACP-01) -... - August 31st, 2021
- 2021 Pipeline Insight Report on Myocardial Infarction - Featuring AstraZeneca, Mesoblast and Boehringer Ingelheim Among Others -... - August 31st, 2021
- Mini brains grown in the lab sprout primitive eyes - Freethink - August 31st, 2021
